Corynebacterium striatum: Difference between revisions
From IDWiki
Corynebacterium striatum
Content deleted Content added
mNo edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
==Management== |
==Management== |
||
*Only reliably susceptible to [[vancomycin]], [[daptomycin]], and [[linezolid]] (essentially 100% susceptibility)[[CiteRef::neemuchwala2018in]] |
*Only reliably susceptible to [[vancomycin]], [[daptomycin]], and [[linezolid]] (essentially 100% susceptibility)[[CiteRef::neemuchwala2018in]][[CiteRef::milosavljevic2021an]] |
||
**Next-best oral option is [[tetracycline]], but only has 35% susceptibility, or [[co-trimoxazole]] (similar susceptibility) |
**Next-best oral option is [[tetracycline]], but only has 35% susceptibility, or [[co-trimoxazole]] (similar susceptibility) |
||
**Sometimes [[ciprofloxacin]] (best of the fluoroquinolones) |
|||
**Other options include [[quinupristin-dalfopristin]] (100%), [[aminoglycosides]] (93%), and [[rifampin]] (85%) |
**Other options include [[quinupristin-dalfopristin]] (100%), [[aminoglycosides]] (93%), and [[rifampin]] (85%) |
||
**Rare susceptibility to beta lactams (ranging from [[amoxicillin]] to [[ceftriaxone]] to [[meropenem]]) and [[clindamycin]] |
|||
[[Category:Gram-positive bacilli]] |
[[Category:Gram-positive bacilli]] |
||
Latest revision as of 15:06, 9 September 2025
Management
- Only reliably susceptible to vancomycin, daptomycin, and linezolid (essentially 100% susceptibility)12
- Next-best oral option is tetracycline, but only has 35% susceptibility, or co-trimoxazole (similar susceptibility)
- Sometimes ciprofloxacin (best of the fluoroquinolones)
- Other options include quinupristin-dalfopristin (100%), aminoglycosides (93%), and rifampin (85%)
- Rare susceptibility to beta lactams (ranging from amoxicillin to ceftriaxone to meropenem) and clindamycin
References
- ^ Alefiya Neemuchwala, Deidre Soares, Vithusha Ravirajan, Alex Marchand-Austin, Julianne V. Kus, Samir N. Patel. In Vitro Antibiotic Susceptibility Pattern of Non-diphtheriae Corynebacterium Isolates in Ontario, Canada, from 2011 to 2016. Antimicrobial Agents and Chemotherapy. 2018;62(4). doi:10.1128/aac.01776-17.
